Status:
COMPLETED
A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This was the first evaluation of the effects of LCZ696 on local and regional measures of aortic stiffness in subjects with mild to moderate hypertension and widened pulse pressure. The results of this...
Eligibility Criteria
Inclusion
- Key Inclusion Criteria:
- Subjects with essential hypertension, untreated or currently taking antihypertensive therapy
- Key exclusion Criteria:
- women of child bearing potential (WOCBP) if not on highly effective contraception
- Malignant or severe hypertension (grade 3 of WHO classification)
- History or evidence of a secondary form of hypertension
- Transient ischemic cerebral attack (TIA) during the 12 months prior to screening or any history of stroke.
- Previous or current diagnosis of heart failure (New York Heart Association Class II-IV).
Exclusion
Key Trial Info
Start Date :
October 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2015
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT01870739
Start Date
October 1 2013
End Date
June 1 2015
Last Update
January 5 2021
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Berlin, Germany, 10117
2
Novartis Investigative Site
Erlangen, Germany, 91054
3
Novartis Investigative Site
Basel, Switzerland, 4031
4
Novartis Investigative Site
Glasgow, Scotland, United Kingdom, G12 8TA